Maxigen Biotech Inc. Wins 2023 Asia's Leading SMEs Award for Innovative Sustainability

KUALA LUMPUR,Malaysia,Sept. 13,2023 -- Maxigen Biotech Inc.(MBI),a pioneering biotech company headquartered in Taiwan,has been honored with the prestigious 2023 Asia's Leading SMEs Award by ACES underscoring its commitment to innovation and sustainable operations.

MBI's ESG-centered business model,innovation,and adaptability showcase Taiwan's exceptional biotech prowess and commitment to lasting value.

Organized by MORS Group,the ACES Awards,held annually,is a symbol of excellence,and this accolade recognizes MBI as an outstanding Asian small and medium-sized enterprise. MBI stands out for its ESG-focused sustainable business model,robust customer base,innovative product supply,consistent revenue and profit growth,and agility in responding to rapidly changing customer demands. MBI not only epitomizes quality assurance through MIT representation but also provides comprehensive solutions within the biotech industry chain,reflecting Taiwan's exceptional performance in global biotechnology and fostering sustainable value.

Since 1998,MBI has been dedicated to researching collagen and hyaluronic acid technologies. Its products span five major sectors: orthopedics,dentistry,medical aesthetics,surgery,and ophthalmology. With certifications from the EU CE,US FDA,MDSAP quality system,and China NMPA,MBI holds an impressive total of 68 product certifications. Its products are distributed across more than 22 countries in North America,Europe,Asia,and Africa. Notably,12 medical devices certifications are held in countries such as Malaysia,Indonesia,the Philippines,and Vietnam,bringing new vitality to the ASEAN market.

Participating in the upcoming 2023 Medica Asia,a renowned medical exhibition in Asia,MBI will collaborate with TCI Group to showcase their synergy in gene testing and advanced medical materials. By harnessing resource complementarity,we aim to strengthen their competitiveness and establish the TCI Biotech Industry Alliance. The alliance provides customers with diverse biotech product combinations and comprehensive integration services. Incorporating VR technology,attendees can experience MBI's professional R&D processes,gaining swift insight into the company's exceptional advantages. Projected estimates indicate a Compound Annual Growth Rate (CAGR) of 7.59% for the ASEAN medical devices market by 2028,underscoring the exhibition's potential to help clients pre-plan and capitalize on substantial business opportunities.

2023 Medica Asia Information

Date: 2023/9/13 (Wed)-2023/9/15 (Fri)

Time: 10:00-18:00

Venue: Bangkok International Trade and Exhibition Center

MBI's booth number: P28